<DOC>
	<DOC>NCT01664845</DOC>
	<brief_summary>The aim of the study is to investigate the treatment response of metformin, Peg-IFN and ribavirin combination therapy for chronic hepatitis C virus (HCV).</brief_summary>
	<brief_title>Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance</brief_title>
	<detailed_description>Current standard of treatment for HCV with pegylated interferon(Peg-IFN)-alpha and ribavirin can achieve sustained virological response (SVR) in only 60-90% of patients. Insulin resistance is an important factor of non-response to combination therapy. Metformin is a insulin sensitizer and can effectively reduce insulin resistance. The aim of the study is to investigate the treatment response of metformin, Peg-IFN and ribavirin combination therapy for chronic HCV.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>HCV RNA (+) and ALT &gt; 40 U/L Compensated liver HOMAIR &gt; 2 neutrophil ï¼œ1500/mm3 male: Hb &lt; 13 g/dl, female: Hb &lt; 12 g/dl platelet &lt; 80,000 /mm3 Cr &gt; 2.5 mg/dl Alcohol use &gt; 20 gm per day uncontrolled depression, thyroid disease, autoimmune disease Pregnancy Hepatocellular carcinoma allergy to interferon or ribavirin Diabetes HBV/HIV coinfection</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>hepatitis c</keyword>
	<keyword>metformin</keyword>
	<keyword>pegylated interferon</keyword>
</DOC>